Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVS/Caremark settles with states

Executive Summary

Firm settles multi-state consumer protection investigation into PBM practices, including therapeutic switching by its legacy AdvancePCS and Caremark subsidiaries by agreeing to payments of up to $41 million. Led by the Illinois and Maryland attorneys general, the investigation by a total of 28 states began in 2004. Of the total payment amount, $38.5 million will go to the states and up to $2.5 million will be allocated to patients who had to undergo medical tests related to switches of cholesterol-reducing drugs. A consent order also restricts therapeutic interchanges by the PBM and requires greater transparency from the company regarding its incentives for switches. CVS/Caremark maintains the agreement involves no admission of wrongdoing on its part. The firm settled federal charges against its legacy subsidiaries in 2005 (1"The Pink Sheet," Sept. 12, 2005, p. 13)...

You may also be interested in...



Caremark False Claims Act Settlement Could Be Framework For State Cases

Caremark's focus on resolving allegations of kickbacks and false claims related to its AdvancePCS subsidiary is expected to shift to state investigations following a $137.5 mil. settlement with federal prosecutors

Amid Aborted Sandoz Deal, A Silver Lining For Aurobindo?

The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.

NanoBio Nasal Antiseptic Launch Accelerated As COVID-19 Spikes Demand For Personal Sanitizers

“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.

UsernamePublicRestriction

Register

PS049306

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel